Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculous tenosynovitis and bursitis: imaging findings in 21 cases.

Radiology·1996
Same author

Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft.

Circulation·1996
Same author

Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·1996
Same author

Differences in cholinergic responses from outer hair cells of rat and guinea pig.

Hearing research·1996
Same author

Pharmacokinetics of retinoids in women after meal consumption or vitamin A supplementation.

Journal of clinical pharmacology·1996
Same author

Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

The Journal of biological chemistry·1996

Related Experiment Videos

Tuberculosis regimen change in high-burden countries.

W A Wells1, N Konduri, C Chen

  • 1Global Alliance for TB Drug Development, New York, New York 10005, USA. william.wells@tballiance.org

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|December 15, 2010
PubMed
Summary

Implementing tuberculosis (TB) regimen changes requires robust planning, focusing on program logistics and patient needs. Early engagement of all stakeholders is crucial for successful, timely roll-out of new TB treatments.

Related Experiment Videos

Area of Science:

  • Public Health
  • Infectious Diseases
  • Global Health

Background:

  • Past tuberculosis (TB) regimen changes offer valuable lessons for future updates.
  • Understanding the dynamics of TB treatment shifts is essential for effective public health strategies.

Purpose of the Study:

  • To examine the process, key stakeholders, and success factors in recent public sector TB regimen changes.
  • To identify challenges and best practices in implementing new TB treatment guidelines.

Main Methods:

  • Conducted 166 interviews with country stakeholders across 21 high-burden TB countries (HBCs).
  • Focused on exploring decision-making processes and implementation factors for drug-susceptible TB regimen changes.

Main Results:

  • Forty distinct regimen changes were identified, with decision-making averaging one year and roll-out two years.
  • Programmatic concerns (logistics, cost) often overshadowed patient-focused issues, with limited patient representative involvement.
  • Implementation faced challenges in drug management and local manufacturing, highlighting the need for early engagement of supply chain and regulatory bodies.

Conclusions:

  • Future TB regimen changes necessitate strengthened decision-making bodies with patient input.
  • Comprehensive planning addressing local implementation realities and evidence gaps is vital for successful TB treatment updates.
  • Integrating practical, patient-centered considerations into regimen change processes is key for improved TB control outcomes.